Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
NHS, Alzheimer's
NHS will not fund new drug to slow Alzheimer’s
A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS, the drugs spending watchdog says. Donanemab was hailed as a turning point in the disease last year.
Alzheimer’s wonder drug blocked on NHS over cost
The most effective drug for Alzheimer’s has been blocked for use on the NHS. Regulators have declared the new treatment for the disease safe for use but the rationing body has immediately ruled that it is too expensive for NHS patients.
Eli Lilly Alzheimer’s Drug Rejected for NHS Use in England
Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.
ITV
9h
Alzheimer’s drug rejected for NHS use: What is Donanemab?
A pioneering new drug, which has been shown to slow the advance of
Alzheimer
's, will not be available to patients on the
NHS
as Ian Woods reports. A new "effective"
Alzheimer
's drug has been ...
Outsourcing-pharma
13h
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
Manchester Evening News on MSN
16h
New Alzheimer’s drug donanemab rejected for widespread use in NHS
A new
Alzheimer
’s drug has been rejected by the health spending watchdog for general use within
NHS
England, with the ...
1d
on MSN
Why thousands of dementia sufferers are being denied the new miracle drug
In late 2022, the results of a groundbreaking stage three trial for a ‘miracle’ new Alzheimer’s drug lecanemab were hailed as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback